Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Deputy Editor

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Richter Swallows Up Estetrol Franchise And More From Stricken Mithra

Gedeon Richter is looking to chart its own path in women’s healthcare and expand its global footprint, after buying up a bundle of businesses and key products and pipeline assets from Belgium’s Mithra.

M & A Deals

Italy Probes Alleged Antitrust Deal Over Biosimilar Version Of Eye Drug Lucentis

Did Samsung Bioepis and Biogen choose early US access for their Lucentis biosimilar in exchange for postponing launch in other markets? That’s what Italy’s competition authority believes, as it investigates the biosimilar sponsors and originator companies Genentech and Novartis.

Regulation Legal Issues

Regeneron Blockade Leaves Biocon Facing 2027 Wait On US Eylea Biosimilar

Biocon has been handed a further setback in its attempts to launch a biosimilar to the market-leading Eylea in the US, after a US district court signed off on a permanent injunction against the Indian firm lasting until June 2027. Meanwhile, decisions on motions for preliminary injunctions against several other biosimilar sponsors are imminent.

Legal Issues Litigation

Lotus Builds In Southeast Asia With Teva Thailand Acquisition

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

M & A Deals

‘Keytruda? We Believe Opdivo Is The Better Choice’: Xbrane’s CEO Martin Åmark

The CEO of Xbrane Biopharma, a Swedish firm focused solely on biosimilar development using a partnered model to potentially take its biosimilars across the globe, speaks exclusively to Generics Bulletin about its ambitions and challenges, including the recent setback for its proposed Lucentis biosimilar in the US.

Biosimilars Strategy

Samsung, Biogen Co-Operate Amid Italian Antitrust Investigation Into Biosimilar Lucentis

Did Samsung Bioepis and Biogen choose early US access for its Lucentis biosimilar in exchange for postponing launch in other global markets? That’s what Italy’s competition authority believes, as it kicked off an investigation into both the biosimilar sponsors and originators Genentech and Novartis.

Regulation Legal Issues
See All
UsernamePublicRestriction

Register